{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T11:05:00Z","timestamp":1761649500367,"version":"3.44.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["kidneymedicinejournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney Medicine"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.xkme.2025.101060","type":"journal-article","created":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T20:02:29Z","timestamp":1750968149000},"page":"101060","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Long-Acting Cabotegravir and Rilpivirine Treatment for HIV in Patients With Kidney Failure: Two Cases of Successful Transition to Long-Acting Injectable HIV Therapy"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8078-9667","authenticated-orcid":false,"given":"Kristi C.","family":"Hill","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Thornton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Willa","family":"Cochran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christin","family":"Kilcrease","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew M.","family":"Hamill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"36","key":"10.1016\/j.xkme.2025.101060_bib1","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000008046","article-title":"Tenofovir alafenamide nephrotoxicity in an HIV-positive patient: a case report","volume":"96","author":"Novick","year":"2017","journal-title":"Med (Baltim)"},{"issue":"4","key":"10.1016\/j.xkme.2025.101060_bib2","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1089\/aid.2023.0108","article-title":"Favorable virological outcome, characteristics of injection site reactions, decrease in renal function biomarkers in Asian people with HIV receiving long-acting cabotegravir plus rilpivirine","volume":"40","author":"Adachi","year":"2024","journal-title":"AIDS Res Hum Retrovir"},{"key":"10.1016\/j.xkme.2025.101060_bib3","unstructured":"Benn P. Renal\/bone outcomes after long-acting cabotegravir+ rilpivirine in ATLAS+ ATLAS-2M. Paper presented at Conference on Retroviruses and Opportunistic Infections; March 6-10, 2021; Virtual. 2021;4:26-28."},{"issue":"6","key":"10.1016\/j.xkme.2025.101060_bib4","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1097\/QAD.0b013e32835cee6e","article-title":"Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials","volume":"27","author":"Cohen","year":"2013","journal-title":"AIDS"},{"issue":"5","key":"10.1016\/j.xkme.2025.101060_bib5","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/cpdd.664","article-title":"A phase I study to evaluate the pharmacokinetics and safety of cabotegravir in adults with severe renal impairment and healthy matched control participants","volume":"8","author":"Parasrampuria","year":"2019","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"1","key":"10.1016\/j.xkme.2025.101060_bib6","doi-asserted-by":"crossref","first-page":"S540","DOI":"10.1093\/ofid\/ofab466.1094","article-title":"899. Use of Dolutegravir\/Rilpivirine in Treatment of HIV in PLWH with CKD and ESRD","volume":"8","author":"Kang","year":"2021","journal-title":"Open Forum Infect Dis"},{"issue":"12","key":"10.1016\/j.xkme.2025.101060_bib8","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1056\/NEJMoa1904398","article-title":"Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression","volume":"382","author":"Swindells","year":"2020","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.xkme.2025.101060_bib9","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1056\/NEJMoa1909512","article-title":"Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection","volume":"382","author":"Orkin","year":"2020","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.xkme.2025.101060_bib10","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1093\/cid\/ciad020","article-title":"Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with human immunodeficiency virus 1 type 1 infection: 152-week results from ATLAS-2M, a randomized, open-label, phase 3b, noninferiority study","volume":"76","author":"Overton","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.xkme.2025.101060_bib11","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/QAI.0000000000001642","article-title":"North American AIDS Cohort Collaboration on Research and Design of IeDEA. Recent abacavir use increases risk of type 1 and type 2 myocardial infarctions among adults with HIV","volume":"78","author":"Elion","year":"2018","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"5","key":"10.1016\/j.xkme.2025.101060_bib12","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1111\/ajt.16205","article-title":"A prospective multicenter pilot study of HIV-positive deceased donor to HIV-positive recipient kidney transplantation: HOPE in action","volume":"21","author":"Durand","year":"2021","journal-title":"Am J Transplant"},{"issue":"9","key":"10.1016\/j.xkme.2025.101060_bib14","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1097\/QAD.0000000000003567","article-title":"Use of long-acting cabotegravir + rilpivirine during hemodialysis and solid organ transplantation","volume":"37","author":"Rezzonico","year":"2023","journal-title":"AIDS"},{"issue":"7","key":"10.1016\/j.xkme.2025.101060_bib15","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s40262-021-01005-1","article-title":"Pharmacokinetics and drug-drug interactions of long-acting intramuscular cabotegravir and rilpivirine","volume":"60","author":"Hodge","year":"2021","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"10.1016\/j.xkme.2025.101060_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195443","article-title":"Chronic kidney disease in the global adult HIV-infected population: A systematic review and meta-analysis","volume":"13","author":"Ekrikpo","year":"2018","journal-title":"PLOS One"},{"issue":"6","key":"10.1016\/j.xkme.2025.101060_bib17","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1093\/cid\/ciu919","article-title":"North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of the International Epidemiologic Databases to Evaluate AIDS (IeDEA). End-stage renal disease among HIV-infected adults in North America","volume":"60","author":"Abraham","year":"2015","journal-title":"Clin Infect Dis"}],"container-title":["Kidney Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059525000962?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059525000962?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T21:18:16Z","timestamp":1757107096000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590059525000962"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S2590059525000962"],"URL":"https:\/\/doi.org\/10.1016\/j.xkme.2025.101060","relation":{},"ISSN":["2590-0595"],"issn-type":[{"type":"print","value":"2590-0595"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-Acting Cabotegravir and Rilpivirine Treatment for HIV in Patients With Kidney Failure: Two Cases of Successful Transition to Long-Acting Injectable HIV Therapy","name":"articletitle","label":"Article Title"},{"value":"Kidney Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xkme.2025.101060","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}],"article-number":"101060"}}